George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

Better Buy: AbbVie vs. Eli Lilly

AbbVie and Eli Lilly have both stumbled this year. Which of these top pharma stocks is better positioned for a rebound?

Is Dynavax Technologies a Buy?

Dynavax's stock surged higher in August. Can this small-cap biotech keep churning higher?

3 Top Biotech Stocks to Buy Right Now

Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.